Real‐World Outcomes of Patients with Metastatic Non‐Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval

BACKGROUND. Evidence from cancer clinical trials has strong internal validity but can be difficult to generalize to real‐world patient populations. Here we analyzed real‐world outcomes of patients with metastatic non‐small cell lung cancer (mNSCLC) treated with programmed cell death protein 1 (PD‐1)...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncologist
Auteurs principaux: Khozin, Sean, Carson, Kenneth R., Zhi, Jizu, Tucker, Melisa, Lee, Shannon E., Light, David E., Curtis, Melissa D., Bralic, Marta, Kaganman, Irene, Gossai, Anala, Hofmeister, Philip, Torres, Aracelis Z., Miksad, Rebecca A., Blumenthal, Gideon Michael, Pazdur, Richard, Abernethy, Amy P.
Format: Artigo
Langue:Inglês
Publié: John Wiley & Sons, Inc. 2018
Sujets:
Lung Cancer
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6516117/
https://ncbi.nlm.nih.gov/pubmed/30591549
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0307
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires